Ignite Creation Date:
2024-05-06 @ 1:45 PM
Last Modification Date:
2024-10-26 @ 1:19 PM
Study NCT ID:
NCT04116242
Status:
COMPLETED
Last Update Posted:
2024-06-25
First Post:
2019-10-03
Brief Title:
MERTK Signalling in MonocytesMacrophages in Patients With Liver Disease
Sponsor:
University Hospital Basel Switzerland
Organization:
University Hospital Basel Switzerland
Study Overview
Official Title:
MERTK Signalling in MonocytesMacrophages in Patients With Liver Disease
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
Recruiting
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to investigate MER receptor tyrosine kinase MERTK signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease Child A B C acute decompensation acute-on-chronic liver failure ACLF and in comparison to patients with acute liver failure and to healthy controls
Detailed Description:
MER receptor tyrosine kinase MERTK signalling cascade becomes activated on monocytesmacrophages during disease progression of liver cirrhosis from Child Pugh A to BC corresponding to early stages of decompensation and before the receptor expression is increased Factors involved in activation of the MERTK signalling cascade might be microbial products such as bacterial deoxyribonucleic acid DNA and other toll-like receptor TLR-ligands MERTK ligands and cytokines as shown elevated in cirrhotic patients
Given the observation that MERTK levels peak on the day of admission with organ failure and decrease in patients surviving the episode of acute-on-chronic liver failure ACLF MERTK Inhibition at a time during progression of cirrhosis but before manifestation of acute decompensation with no cirrhosis AD or ACLF might prevent infectious complications decompensation and improve survival in patients with cirrhosis
This study is to investigate MER receptor tyrosine kinase MERTK signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease Child A B C acute decompensation acute-on-chronic liver failure ACLF and in comparison to patients with acute liver failure and to healthy controls
Given the observation that MERTK levels peak on the day of admission with organ failure and decrease in patients surviving the episode of acute-on-chronic liver failure ACLF MERTK Inhibition at a time during progression of cirrhosis but before manifestation of acute decompensation with no cirrhosis AD or ACLF might prevent infectious complications decompensation and improve survival in patients with cirrhosis
This study is to investigate MER receptor tyrosine kinase MERTK signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease Child A B C acute decompensation acute-on-chronic liver failure ACLF and in comparison to patients with acute liver failure and to healthy controls
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None